Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588792 | 0.87 | ALDH1A1 (0.40) | ALDH1A1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31095270 | 0.87 | ALDH1A1 (0.40) | ALDH1A1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3720623 | 0.84 | HTT (0.54) | ALDH1A1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL857818 | 0.81 | KDM4E (0.48) | ALDH1A1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL29532068 | 0.81 | KDM4E (0.48) | ALDH1A1KMT2AKDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL28031937 | 0.80 | BCHE (0.48) | ALDH1A1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL11345513 | 0.79 | KDM4E (0.36) | ALDH1A1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL21707870 | 0.77 | KMT2A (0.51) | ALDH1A1KMT2AKDM4ELMNAGAA | |
| SCHEMBL7162825 | 0.77 | SMN1; SMN2 (0.39) | ALDH1A1PDE3BPDE3AKDM4EHTT | |
| SCHEMBL21642441 | 0.76 | PDE3B (0.43) | ALDH1A1PDE3BPDE3AKMT2AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| WO-2018201006-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| US-4102885-A | Process for preparing 2,4-dihaloquinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | ALDH1A1 1422/4885TUBB4A 3502/4885TUBB 4316/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | ALDH1A1 1422/4885TUBB4A 3502/4885TUBB 4316/4885 |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | SLC2A3, SLC2A4, SLC2A1 | ALDH1A1 1987/4885TUBB4A 3149/4885TUBB 3768/4885 |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | SLC2A3, SLC2A4, SLC2A1 | ALDH1A1 1987/4885TUBB4A 3149/4885TUBB 3768/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | ALDH1A1 1565/4885TUBB4A 3380/4885TUBB 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.